This HTML5 document contains 42 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n10http://bio2rdf.org/drugbank:
n8http://linked.opendata.cz/resource/drugbank/drug/DB08848/identifier/kegg-compound/
admshttp://www.w3.org/ns/adms#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n7http://linked.opendata.cz/resource/drugbank/drug/DB08848/identifier/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB08848
rdf:type
n3:Drug
n3:description
Guvacine is a pyridine alkaloid found in the Areca nut (also known as the Betel nut). It is an experimental drug with no approved indication. Experimental studies are still being investigated to determine all of the physiological effects and mechanisms of action of guvacine. Currently it has been determined that guvacine is a specific GABA reuptake inhibitor with no significant affinity at GABA receptors.
n3:generalReferences
# The Merck Index monographs. # Krogsgaard-Larsen P, Frolund B, Frydenvang K: GABA uptake inhibitors. Design, molecular pharmacology and therapeutic aspects. Curr Pharm Des. 2000 Aug;6(12):1193-209. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10903390
n3:group
experimental
n3:indication
There is no approved indication for guvacine.
owl:sameAs
n10:DB08848
dcterms:title
Guvacine
adms:identifier
n7:DB08848 n8:C10149
n3:mechanismOfAction
Experimental studies are still being investigated to determine the exact mechanisms of action of guvacine. What is known is that guvacine binds selectively to presynaptic GABA reuptake transporters and prevents the reuptake of GABA, but has no affinity for GABA postsynaptic receptors.
n3:salt
n3:synthesisReference
McELVAIN SM, STORK G: Piperidine derivatives; the preparation of l-benzoyl-3-carbethoxy-4-piperidone; a synthesis of guvacine. J Am Chem Soc. 1946 Jun;68:1049-53.
n3:IUPAC-Name
n4:271B58E9-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B58EF-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B58EE-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B58EB-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B58EC-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B58ED-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B58FF-363D-11E5-9242-09173F13E4C5 n4:271B58E7-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B58E5-363D-11E5-9242-09173F13E4C5 n4:271B58E8-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B58E6-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B58F5-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B58F6-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B58F0-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B58F1-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B58F3-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B58F2-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B58F4-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
498-96-4
n3:Bioavailability
n4:271B58FB-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B58FD-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B58FE-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B5900-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B58FA-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B58F9-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B58FC-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B58EA-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B58F7-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B58F8-363D-11E5-9242-09173F13E4C5